Pfizer Outperforms Moderna in Post-COVID Earnings

In Q4 2025, Pfizer (PFE) outperformed expectations with a diversified non-COVID portfolio and strategic moves into obesity drugs. In contrast, Moderna (MRNA) faced declining revenue but managed to beat loss estimates through cost cuts.

By Vandita Jadeja May 4, 2026 4 min read · Yahoo Finance · May 4, 2026, 14:09 UTC

Pfizer Outperforms Moderna in Post-COVID Earnings

Tickers: $MRNA $PFE

Topics: diversification strategy mRNA technology obesity drugs pharmaceuticals

Read the full article at Yahoo Finance

More World news

Linnworks Survey Reveals US E-commerce Businesses Limit AI Role to Operational Support Over Financial Control PR Newswire · November 12, 2026, 13:43 UTC
DocsInk Rebrands as TraceWell Health and Launches Integrated Care Platform PR Newswire · November 12, 2026, 13:44 UTC
Zoom Ventures Invests in Medaica to Advance AI-Powered Virtual Healthcare Seeking Alpha · November 12, 2026, 13:40 UTC
Rival Technologies Index Reveals Gen Z Financial Constraints Amidst Optimistic Outlook PR Newswire · November 12, 2026, 13:42 UTC
Canadian Cybersecurity Job Postings Rise While Entry-Level Opportunities Decline PR Newswire · November 12, 2026, 13:42 UTC
Klarna Appoints Robinhood's Chris Koegel as Chief Financial Officer Seeking Alpha · November 12, 2026, 13:35 UTC
Kyverna Therapeutics Reports Q3 GAAP EPS of -$0.68, Slightly Beating Estimates Seeking Alpha · November 12, 2026, 13:37 UTC
TelyRx Holdings Appoints Co-Founder Benjamin Atkins as Interim CEO Seeking Alpha · November 12, 2026, 13:38 UTC
Nvidia shares fall following analyst downgrades and reports of potential CEO leadership changes Seeking Alpha · November 12, 2026, 13:38 UTC
Technosylva Launches Technosylva Planning Application for Multi-Hazard Utility Risk Management PR Newswire · November 12, 2026, 13:38 UTC